 |
|
Proud producer of the 2017 BioNJ Dr. Sol J. Barer Award video featuring industry icon Fred Hassan.
|
 |
|
This edition of
BioLines Weekender
is in honor of the Rare Disease community.
BioNJ is pleased to participate in Rare Disease Day 2017 in Trenton on Monday, February 27, at the New Jersey Business and Industry Association (NJBIA).
Bringing together Patients, Patient advocates, legislators, biomedical healthcare professionals and industry leaders, this year's Rare Disease Day commemoration will be focused on "Innovation, Research and Access."
H
ighlights will include real world Patient stories, insights into effectively including the Patient voice in drug development,
the climate of innovation in New Jersey for Rare Disease drug and device development, information
about the Catastrophic Illness in Children Relief Commission, updates on the growing academic research community in the State and legislation that supports the needs of people with rare diseases.
In addition, members of the New Jersey Legislature will present a ceremonial resolution commemorating Rare Disease Day 2017 in New Jersey.
Because Patients Can't Wait®, we hope you will join us in Trenton. Click here
to learn more.
Visit
www.BioNJ.org for BioNJ's
calendar of events, including our upcoming Career/Connection Industry Job Fair on April 26 and BioPartnering Conference on May 23.
Because Patients Can't Wait®,
The BioNJ Team
|
 |
BioNJ Calendar |
 |
|
|
|
Rare Disease Day
|
|
Feb. 27, 2017
|
|
Manufacturing Breakfast Briefing
|
|
March 30, 2017
|
|
BIO Fly-In
Washington, D.C.
|
|
April 4-5, 2017
|
|
BioNJ Career/Connection Industry Job Fair
Livingston Student Center, Rutgers University
|
|
April 26, 2017
Save the Date!
|
|
BioNJ BioPartnering 2017 Conference
Busch Student Center, Rutgers University
|
|
May 23, 2017
Save the Date!
|
|
|
|
Putting Patients First: The Value of Medical Innovation
Brought to You by Celgene Corporation |
 |
|
|
|
Summit-based BioNJ Member Celgene Corporation has provided a detailed look at its progress in fulfilling its corporate responsibility in 2016. The report, "Patients First," highlights the company's policies and achievements, including publishing principles for the pricing of innovative medicines, using renewable energy and expanding its engagements with stakeholders around the world.
|
|
|
|
BioNJ in the News |
 |
|
|
|
The New Jersey Rare Disease Alliance, dedicated to improving the lives of the more than 800,000 rare disease patients in New Jersey, will hold its annual Rare Disease Day commemoration on Monday, February 27, at the New Jersey Business and Industry Association (NJBIA), 10 West Lafayette Street, Trenton from 9:00 a.m.-12:00 p.m. The event, sponsored by BioNJ, National Organization for Rare Disease (NORD) and the Healthcare Institute of NJ, the program will begin with networking followed by speakers from the rare disease community including patients, patient advocates, legislators, biomedical healthcare professionals and industry leaders.
|
|
|
|
NJ Company News |
 |
|
|
|
Ever proud of our ecosystem, we are pleased to share our Company News. Be sure to click on the article titles below to read the full release.
|
|
Parsippany-based BioNJ Member The Medicines Company announced that the
U.S. Food and Drug Administration
(
FDA
) has accepted for priority review the company's new drug application (NDA) filing for Carbavance® (meropenem-vaborbactam) for the treatment of complicated urinary tract infections (cUTIs). The NDA filing is based on results from the pivotal Phase III TANGO 1 clinical trial in patients with cUTIs.
|
|
|
|
Cranbury-based BioNJ Member
Amicus Therapeutics
presented additional positive preliminary data from a global Phase 1/2 study (ATB200-02) to investigate ATB200/AT2221 in a poster at the 13th Annual WORLDSymposium™
.
ATB200/AT2221 is a novel treatment paradigm that consists of ATB200, a unique recombinant human acid alpha-glucosidase (rhGAA) enzyme with optimized carbohydrate structures, particularly mannose-6 phosphate (M6P), to enhance uptake, co-administered with AT2221, a pharmacological chaperone.
|
|
|
|
Princeton-based BioNJ Member Otsuka Pharmaceutical Co., Ltd. and Lundbeck Canada announce that Health Canada issued a Notice of Compliance for REXULTI™ (brexpiprazole) for the treatment of schizophrenia in adults. REXULTI™ was discovered by Otsuka and co-developed with Lundbeck. It will be co-marketed by the two companies and is expected to become commercially available in Canada this spring.
|
|
|
|
Berkeley Heights-based BioNJ Member Chugai Pharmaceutical Co., Ltd. announced that F. Hoffmann-La Roche Ltd. obtained conditional marketing authorization from the European Commission (EC), for the anti-cancer agent, alectinib hydrochloride (brand name: Alecensa®) for the treatment of adult patients with "anaplastic lymphoma kinase (ALK) positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or those intolerant to crizotinib."
|
|
|
|
BioNJ Member Jazz Pharmaceuticals plc, with offices in Ewing, announced that the first patient has been enrolled in a Phase 2 clinical study evaluating JZP-110, a selective dopamine and norepinephrine reuptake inhibitor, as a potential treatment for excessive sleepiness (ES) in adult patients with Parkinson's disease. The clinical study will be conducted across approximately 15 centers in the United States.
|
|
|
|
East Hanover-based BioNJ Member Novartis announced that the U.S. Food and Drug Administration (FDA) accepted the company's supplemental New Drug Application (sNDA) for filing, and granted Priority Review for the expanded use of Zykadia® (ceritinib) as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. The FDA also granted Breakthrough Therapy designation to Zykadia for the first-line treatment of patients with ALK+ metastatic NSCLC with metastases to the brain.
|
|
|
|
BioNJ Member Pfizer Inc., with offices in Madison, announced that a Biologics License Application (BLA) for inotuzumab ozogamicin has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA). Inotuzumab ozogamicin is being evaluated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
|
|
|
|
BioNJ Member Pfizer Inc., with offices in Madison, announced top-line results from ORAL Strategy, a Phase 3B/4 study of XELJANZ® (tofacitinib citrate) 5mg twice daily (BID) in the treatment of moderate to severe rheumatoid arthritis (RA). ORAL Strategy is the first trial to compare a JAK inhibitor as monotherapy or in combination with methotrexate (MTX) versus adalimumab (Humira) plus MTX in MTX inadequate responders using ACR50 at Month 6 as the primary endpoint.
|
|
|
|
Data announced jointly by BioNJ Member Pfizer Inc. and Celltrion Healthcare showed that for patients with moderate-to-severe Crohn's disease (CD), treatment with INFLECTRA (infliximab CT-P13) has similar efficacy and safety to treatment with REMICADE (infliximab). The randomized 54 week clinical trial (RCT)2 in 214 patients met its primary end point demonstrating that, at six weeks, INFLECTRA was similar to REMICADE in the treatment of CD thereby meeting the criterion for non-inferiority.
|
|
|
|
Bridgewater-based BioNJ Member
Eli Lilly and Company
and
Incyte Corporation
announced that the
European Commission
has granted marketing authorisation for Olumiant® (baricitinib) 4 mg and 2 mg film-coated tablets in
Europe
for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs).
|
|
|
|
Bridgewater-based BioNJ Member
Eli Lilly and Company
and
Incyte Corporation
announced additional detailed results from RA-BEAM, a pivotal Phase 3 study of baricitinib in the treatment of moderate-to-severe rheumatoid arthritis (RA), were published in the New England Journal of Medicine. The publication includes supplementary data, which show that starting as early as week 8, and sustained through week 52, a higher proportion of patients taking baricitinib achieved ACR50 and ACR70 response -- composite scores that represent at least 50 percent and 70 percent improvement, respectively, in multiple components of RA disease activity -- compared to adalimumab (Humira®).
|
|
|
|
Titusville-based BioNJ Member Janssen Research & Development, LLC announced that the Phase 3 COMPASS trial, evaluating the efficacy and safety of XARELTO® (rivaroxaban) for the prevention of major adverse cardiac events (MACE), including cardiovascular death, myocardial infarction and stroke in patients with coronary artery disease (CAD) or with peripheral artery disease (PAD), is stopping earlier than planned.
|
|
|
|
Rutherford-based BioNJ Member Cancer Genetics, Inc., a leader in precision diagnostics for oncology, announced that its hereditary cancer panel, Focus::HERSite™, for breast and ovarian cancer, has been selected by a global pharmaceutical company for a 1,000+ patient clinical study. The study will determine how inherited mutations associated with cancer will impact therapy response and cancer progression in breast cancer.
|
|
|
|
Parsippany-based BioNJ Member Ferring Pharmaceuticals and Foresee Pharmaceuticals Co., Ltd. announced that the companies have entered into an exclusive worldwide development and option agreement to leverage Foresee's proprietary and unique Stabilized Injectable Formulation platform (SIF) for the development of long duration, controlled release formulations of a peptide therapeutic.
|
|
|
|
Kenilworth-based BioNJ Member Merck announced results of a pivotal Phase 3 clinical trial evaluating the safety and efficacy of doravirine (MK-1439), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). The study met its primary efficacy endpoint of the proportion of participants achieving levels of HIV-1RNA less than 50 copies/mL after 48 weeks of treatment, demonstrating the non-inferiority of once-daily doravirine (DOR) to once-daily ritonavir-boosted darunavir (DRV+r), each administered with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/3TC), in previously untreated (treatment-naïve) adults with HIV-1 infection.
|
|
|
|
Morris Plains-based BioNJ Member Immunomedics announced that sacituzumab govitecan (IMMU- 132) is active in patients with metastatic urothelial cancer (UC) and has the potential to become a second line or later treatment to platinum-based or immuno-oncology therapy for these patients.
|
|
|
|
Morris Plains-based BioNJ Member Immunomedics, Inc. announced that it has entered into an exclusive global licensing
agreement with Seattle Genetics, Inc.
, an innovative global biotechnology company that
develops and commercializes novel antibody
-
drug conjugates (ADCs) for the
treatment of c
ancer
. Under the agreement, Seattle Genetics
will develop, fund, manufacture and commercialize IMMU
-
132, Immunomedics'
proprietary solid tumor therapy candidate.
|
|
|
|
Summit-based BioNJ Member Celgene announced that its Phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly interferon (IFN) β-1a (Avonex®).
|
|
|
|
Iselin-based BioNJ Member Helsinn Group and Mundipharma have expanded their collaboration, signing amendments to licensing and distribution agreements for anti-emetic prophylactic agents ALOXI® and AKYNZEO® to cover a host of additional markets.
|
|
|
|
Basking Ridge-based BioNJ Member Ipsen announced that it has entered into a definitive agreement to acquire from BioNJ Member Sanofi five consumer healthcare products in certain European territories. The most significant product is Prontalgine®, an analgesic for the treatment of moderate to severe pain, which has grown at double digit rates over the last four years and is available only in France.
|
|
|
|
Parsippany-based BioNJ Member Allergan plc, the biopharmaceutical company with its U.S. headquarters in Parsippany, announced that it is paying approximately $2.5 billion for medical technology company Zeltiq Aesthetics Inc. Allergan said the Zeltiq deal will enhance its global medical aesthetics portfolio with the addition of Zeltiq's CoolSculpting System, which it called a sales leader in the $4 billion body contouring, or fat cell reduction, segment.
|
|
|
|
South Plainfield-based BioNJ Member
PTC Therapeutics, Inc.
announced that on February 20, 2017 it approved non-statutory stock options to purchase an aggregate of 55,900 shares of its common stock to 14 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new hires' employment compensation
.
|
|
|
|
Integra Lifesciences Holdings Corp., a Plainsboro-based medical technology company, has made an offer to acquire Johnson & Johnson Codman Neurosurgery business for $1.045 billion. If the offer is accepted by BioNJ Member Johnson & Johnson, Integra said it will be a leading provider of neurosurgical products. The neurosurgery portfolio includes products focused on advanced hydrocephalus, neuro-critical care and operative neurosurgery.
|
|
|
|
Florham Park-based Protalex, Inc., a clinical-stage biopharmaceutical company, provides an update on its U.S. Phase 1/2 and European Phase 1b studies of PRTX-100 in adults with persistent, chronic Immune Thrombocytopenia (ITP). PRTX-100, Protalex's lead drug candidate, is a highly-purified form of Staphylococcal protein A (SpA) and is the subject of ongoing clinical development in ITP and rheumatoid arthritis (RA).
|
|
|
|
Bridgewater-based Valeant Pharmaceuticals International, Inc. announced that the
U.S.
Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for SILIQ™ (brodalumab) injection, for subcutaneous use, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis. SILIQ is indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
|
|
|
|
Bridgewater-based Valeant Pharmaceuticals International, Inc. and EyeGate Pharmaceuticals, Inc. announced that they have entered into an exclusive, worldwide licensing agreement through which EyeGate has granted a subsidiary of Valeant exclusive, worldwide commercial and manufacturing rights to the EyeGate® II Delivery System and
EGP-437
combination product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients.
|
|
|
|
Progenics Pharmaceuticals, Inc., an oncology company developing innovative medicines and other products for targeting and treating cancer, with offices in East Hanover, announced that enrollment of an investigator initiated Phase 1 clinical trial with 131-I-MIP-1095 (1095) has begun at MSK. 1095 is one of Progenics' PSMA-targeted small molecule radiopharmaceutical candidates being developed for the treatment of metastatic prostate cancer.
|
|
|
|
Hackensack-based
BrainStorm Cell Therapeutics Inc.
, a leading developer of adult stem cell technologies for neurodegenerative diseases, has signed an agreement with CCRM, a
Toronto
-based leader in developing and commercializing regenerative medicine technologies, and cell and gene therapies, to support the market authorization request for NurOwn®.
|
|
|
|
Hackensack-based
BrainStorm Cell Therapeutics Inc.
, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that it plans to contract with
City of Hope's Center for Biomedicine and Genetics
to produce clinical supplies of NurOwn® adult stem cells for the company's planned randomized, double-blind, multi-dose Phase 3 clinical study in patients with Amyotrophic Lateral Sclerosis (ALS).
|
|
|
|
Lawrenceville-based
Celsion Corporation
announced the pricing of a public offering with expected total gross proceeds of approximately
$5.0 million
. The offering was priced at
$0.23
per share of common stock (or common stock equivalent), with each share of common stock (or common stock equivalent) sold with one five-year warrant to purchase 0.75 of a share of common stock, at an exercise price of
$0.23
per share.
|
|
|
|
MannKind Corporation, with offices in Paramus, confirmed that it received $16.7 million on February 17, 2017, upon closing the sale of real estate owned by the company in Valencia, California, net of closing costs.
|
|
|
|
Little Falls-based
Cantel Medical Corp. announced that it has agreed to purchase its endoscopy business asset from CR Kennedy & Co. Pty Ltd., an Australian distributor.
The endoscopy business asset consists of Cantel's Medivators-branded product portfolio. "This acquisition is in line with Cantel's strategy to expand its products and services into key markets to provide global solutions that meet local needs," said Jorgen B. Hansen, CEO and President of Cantel Medical.
|
|
|
|
Astellas Pharma, with offices in Cedar Knolls, was recognized as one of 2017's 50 Best Companies for Giving Back in the United States across all industries by consulting firm Great Place to Work® and Fortune magazine. Astellas ranked 25th on the list.
|
|
|
|
What makes a company one of the Best Places to Work in New Jersey? It could be one of many things, from work/life balance to salary and benefits, but something each one of this year's winners shares is a focus on their employees and their professional environment. Congratulations to these BioNJ Members for making NJBIZ's list of Best Places to Work:
Grunenthal USA Inc.,
Ipsen Biopharmaceuticals Inc.,
JBK Associates International,
The Execu|Search Group and
WithumSmith+Brown P.C.
|
|
|
|
Funding News |
 |
|
|
|
Rutherford-based BioNJ Member Cancer Genetics, Inc., an emerging leader in enabling precision medicine for oncology through the use of molecular markers and information, announced that it has received approval for a $1.0 million gross tax credit from the New Jersey Technology Business Tax Certificate Transfer (NOL) Program.
|
|
|
|
Princeton-based BioNJ Member Signum Biosciences, Inc. announced that the National Institute of Allergy and Infectious Diseases (NIAID) awarded the company a Small Business Innovation Research (SBIR) Phase IIB grant totaling $3.0 million over 3 years for the development of a novel topical non-steroidal anti-inflammatory drug candidate for atopic dermatitis (AD).
|
|
|
|
The New Jersey Economic Development Authority (EDA), a BioNJ Member, announced the approval of a record-breaking 251 applications through the State's Angel Investor Tax Credit Program in 2016, representing the injection of more than $96 million in private capital into technology and life sciences companies throughout the Garden State. In the fourth quarter of 2016 alone, the EDA approved 198 applications.
|
|
|
|
Institution and Education News |
 |
|
|
|
As owner of a laboratory that tested pharmaceuticals, Paul Winslow was dismayed by the scarcity of qualified scientists he could hire. After selling his business a decade ago, he tried to do something about the shortage. Dr. Winslow leased space across from a cemetery in East Hanover, N.J., rustled up $4 million worth of donated equipment and recruited volunteer scientists to show teenagers the wonder of real-world experiments.
|
|
|
|
The Greater Philadelphia Region Life Sciences Report ranks BioNJ Members Princeton University, Rowan University and Rutgers-Camden high
among colleges and universities in the region in R&D expenditures related to life sciences. The ranking is based on 2014 figures from the National Science Foundation and includes funds spent on biological sciences, chemical engineering, chemistry, medical sciences and other life sciences.
|
|
|
|
Dr. Mohammad Abedin-Nasab, a research Assistant Professor of Biomedical Engineering in the Henry M. Rowan College of Engineering at BioNJ Member, Rowan University
has developed a robotic device that can assist surgeons in treating patients with broken femurs and other bones in a manner that will enable them to heal a little faster with fewer complications.
|
|
|
|
BioNJ Member Rutgers' Laura Fabris, Ph.D. will play a key role in a project aimed at designing TIPs -- therapeutic interfering particles to defuse the flu. Dr. Fabris and her team will use imaging tools with gold nanoparticles to monitor mutations in the influenza virus, with unprecedented sensitivity, when it enters cells. She will soon receive a $820,000 grant from the Defense Advanced Research Projects Agency (DARPA) -- part of a four-year, $5.2 million INTERfering and Co-Evolving Prevention and Therapy (INTERCEPT) program.
|
|
|
|
A drug commonly given to reduce the side effects of strong post-surgery pain medications has been found to reduce the length of hospital stays for patients who have undergone major gastrointestinal or bladder cancer procedures. An investigator at BioNJ Member Rutgers Cancer Institute of New Jersey explored whether this drug would have a similar impact on patients undergoing surgery for testicular cancer and found use of this drug may facilitate gastrointestinal recovery and have other benefits.
|
|
|
|
Scientists at BioNJ Member Rutgers University say neurodegenerative diseases like Alzheimer's and Parkinson's may be linked to defective brain cells disposing toxic proteins that make neighboring cells sick. In a study published in Nature, Monica Driscoll, distinguished Professor of Molecular Biology and Biochemistry, School of Arts and Sciences, and her team, found that while healthy neurons should be able to sort out and rid brain cells of toxic proteins and damaged cell structures without causing problems, laboratory findings indicate that it does not always occur.
|
|
|
|
The $10 billion Robert Wood Johnson Foundation named its new CEO and President, Dr. Richard Besser. Dr. Besser, who will take office in April, is a former acting Director for the Centers for Disease Control and Prevention and ABC News' current Chief Health and Medical Editor. He succeeds Dr. Risa Lavizzo-Mourey, who led the foundation for 14 years.
|
|
|
|
People in the News |
 |
|
|
|
Berkeley Heights-based BioNJ Member Edge Therapeutics Inc., a Berkeley Heights-based biotechnology company developing therapies to manage life-threatening conditions, announced it has appointed Alyssa Wyant as Senior Vice President, Regulatory Affairs. Ms. Wyant has approximately 20 years of experience in the global regulatory industry. Prior to Edge, she was Vice President, Global Regulatory Affairs at PTC Therapeutics.
|
|
|
|
Newark-based Symbiomix announced it has hired David L. Stern, MBA, a seasoned biopharmaceutical executive with over 20 years of experience leading the commercialization of treatments in women's health and fertility, as Chief Executive Officer of the company.
Mr. Stern joins Symbiomix on the heels of the company's recent submission of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for its drug candidate Solosec™, an innovative antibiotic designed to treat BV.
|
|
|
|
Princeton-based BioNJ Member Genmab A/S announced the appointment of Judith Klimovsky, M.D., as Executive Vice President and Chief Development Officer. Dr. Klimovsky will lead the company's global product development activities and will join the Executive Team of Chief Executive Officer, Dr. Jan van de Winkel and Chief Financial Officer, David Eatwell.
|
|
|
|
The board of directors of Bridgewater-based BioNJ Member
Eli Lilly and Company
has elected
Carolyn R. Bertozzi
, Ph.D., as a new member. As a member of Lilly's board, Dr. Bertozzi will serve on the Science and Technology and Public Policy and Compliance Committees of the board.
|
|
|
|
Medinol, a cardiology device company with U.S. commercial offices in Parsippany, announced it has appointed Harvey J. Berger to Executive Chairman. Mr. Berger will join Medinol's global management team in areas of business management, global strategy, new business and technology initiatives. He will also work with Medinol's cardiovascular devices and other products.
|
|
|
|
Cranbury-based Cornerstone Pharmaceuticals, Inc. announced a number of additions to its Scientific and Medical Advisory Boards, continuing the company's recent momentum of
growth in its management team and
governing and advisory bodies.
|
|
|
|
Princeton-based Adgero Biopharmaceuticals Holdings Inc., a biopharmaceutical company in late-stage photodymanic therapy for treating oncology, announced it has appointed Jane M. Maida its new Chief Financial Officer and vice president of finance. Ms. Maida, who has more than 20 years of industry experience, was previously a CFO at Signum Biosciences Inc.
|
|
|
|
Cranbury-based Purdue Pharma L.P. announced the appointment of Margaret K. Feltz, Esq. to Vice President and Chief Ethics & Compliance Officer, reporting to President and Chief Executive Officer Mark Timney. In this role, Ms. Feltz is responsible for the company's overall ethics and compliance strategy and leadership, technical direction and guidance concerning Purdue business activities, decisions and operations.
|
|
|
|
Upcoming Programs from Our Partners for BioNJ Members |
 |
|
|
|
March 1 | Drexel University, Philadelphia, PA
The World Trade Center of Greater Philadelphia presents the 14th Annual Global Business Conference. 2017 promises to be a year of continued change and challenge in the world economy. Join the region's international business community as we hear from leading economists, trade experts and successful companies on major trends to watch and strategies for success.
|
|
|
|
March 2 | Apella at the Alexandria Center, New York, NY
Building better lives is why the Heart & Stroke Innovation Forum convenes world-renowned experts and leaders in academia, industry and investment for a dialogue on advancing cutting edge cardiovascular and stroke care and innovative ideas.
BioNJ Members are invited to attend at no cost.
To RSVP for a
complimentary ticket, please email Chelsea Beecher at chelsea.beecher@heart.org.
|
|
|
|
March 10 | Hyatt Regency, New Brunswick
New Jersey Future's Redevelopment Forum is a day-long conference that brings together more than 500 municipal and state leaders and leading professionals in planning, development, law, transportation, architecture, construction, environmental conservation and historic preservation to share best practices and lessons learned.
|
|
|
|
March 10 | The Birchwood Manor, Whippany, NJ
The program features a morning panel discussion on "The State of the Life Science Industry within Morris County," followed by a luncheon and Keynote by Jay Bapna, Senior Vice President of Global Engineering & EH&S, Allergan.
|
|
|
|
April 4-5 | Washington D.C.
The BIO Legislative Day Fly In is a free event hosted by BIO as a benefit of BIO membership.
Attendees are invited to participate in a legislative briefing and networking reception on Tuesday. On Wednesday, attendees participate in meetings with Congressional offices of their home states along with other attendees from the same state.
|
|
|
|
April 27 | North Brunswick, NJ
NJ Founders & Funders is organized by the NJEDA Technology & Life Sciences (TLS) team to facilitate warm introductions between emerging New Jersey TLS companies and sophisticated angel and institutional investors. Venture capital investors are invited to meet with a select group of companies for 10-minute, one-on-one sessions to discuss strategy, business models and funding opportunities.
|
|
|
|
September 25-27 | San Jose, CA
AdvaMed 2017 is the leading MedTech conference in North America, bringing more than 1,000 companies together in a uniquely multifaceted environment for business development, capital formation, innovative technology showcasing, world-class educational opportunities and networking. An event rich in international flavor and featuring a deep, diverse attendee list that includes influential policy-makers, business executives and media, AdvaMed 2017 seeks to advance industry discussion from key perspectives through detailed panel sessions, executive forums and more.
|
|
|
|
|
|
|
|
